



OUTCOME OF NEWER FIBRIN SPECIFIC THROMBOLITIC AGENT IN STEMI IN A COMMUNITY HOSPITAL OF NEPAL

Dr Silwal Shivaji Bikram

Head, Department of Cardiology, Scheer Memorial Hospital, Banepa, Kavre

Abstract: BACKGROUND: In the absence of contraindications, fibrinolytic therapy is administered to ST-elevation MI (STEMI) patients with symptom onset within 12 hours after diagnosis of STEMI in partly limited availability of primary percutaneous coronary intervention (PCI) hospital. Reperfusion treatment in acute STEMI represents the main indication for thrombolytic therapy in a community hospital set up.

OBJECTIVE: To study newer fibrin specific thrombolytic agent for the management of acute STEMI.

RESULT: In our study, we had 38 patients presented to the emergency department of Scheer Memorial Hospital and were diagnosed as STEMI presented

Biography: Dr Shivaji Bikram Silwal is a Cardiologist working at Norvic International Hospital, Kathmandu (as Consultant Interventional Cardiologist) and Scheer Memorial Hospital Banepa (as Head, Department of Cardiology).



Publications:

1. Evaluating the Mechanical Properties of Admixed Blended Cement Pastes and Estimating its Kinetics of Hydration by Different Techniques
2. Genetic Diversity Using Random Amplified Polymorphic DNA (RAPD) Analysis for *Aspergillus niger* isolates
3. Au–Ag–Cu nanoparticles alloys showed antifungal activity against the antibiotics-resistant *Candida albicans*
4. Induce mutations for Bavistin resistance in *Trichoderma harzianum* by UV-irradiation
5. Biliary Sludge. Analysis of a Clinical Case

[2nd World cardiology Experts Meeting September 21-22, 2020](#)

Abstract Citation: [Dr. Silwal Shivaji Bikram, OUTCOME OF NEWER FIBRIN SPECIFIC THROMBOLITIC AGENT IN STEMI IN A COMMUNITY HOSPITAL OF NEPAL, WORLD CARDIOLOGY SUMMIT 2020, 2nd World cardiology Experts Meeting, September 21-22, 2020](#)